Back to top
more

Alexion Pharmaceuticals, Inc. (ALXN)

(Delayed Data from NSDQ)

$136.69 USD

136.69
978,618

+3.56 (2.67%)

Updated May 3, 2019 04:00 PM ET

After-Market: $136.70 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

Achillion (ACHN) Shares Down as J&J Announces Stake Sale

Achillion's (ACHN) shares fell following the announcement that J&J will sell its complete stake in the company.

    Achillion (ACHN) Q3 Loss Narrows, Pipeline Expansion in Focus

    Achillion Pharmaceuticals' (ACHN) third-quarter loss was narrower than estimates. The company is focusing on expanding its key pipeline candidate in several indications.

      3 ETFs to Watch on Biotech Earnings

      Major Biotech companies report mixed Q3 results.

        Alexion (ALXN) Tops Q3 Earnings, Lags Sales, 2017 View Up

        Alexion Pharmaceuticals, Inc.???s (ALXN) beat earnings estimates but missed sales estimates in the third quarter of 2017.

          Alexion (ALXN) Tops Q3 Earnings, Sales Miss, Shares Up

          Alexion surpassed earnings expectations but missed sales estimates in the third quarter of 2017.

            Arpita Dutt headshot

            Biotech Stock Roundup: Biogen Tops Q3 Earnings, Gilead's CAR T Drug Gets FDA Nod

            Key highlights include Biogen's (BIIB) Q3 results and regulatory news from companies like Gilead and Alexion.

              Is a Beat in Store for Alexion (ALXN) This Earnings Season?

              Alexion's (ALXN) blockbuster drug, Soliris, continues to perform well and the company is scheduled to report third-quarter 2017 results on Oct 26, before the opening bell.

                Is the Options Market Predicting a Spike in Alexion Pharmaceuticals (ALXN) Stock?

                Surging implied volatility makes Alexion Pharmaceuticals (ALXN) Stock lucrative to the option traders.

                  What's in Store for BioMarin (BMRN) This Earnings Season?

                  BioMarin (BMRN) is likely to see continued momentum in Kuvan sales in Q3. However, slowdown in Federal purchasing orders in Brazil will hurt Naglazyme and Vimizim product revenues.

                    What's in the Cards for Amgen (AMGN) this Earnings Season?

                    While Amgen's (AMGN) growth drugs like Prolia & Xgeva might continue to do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.

                      Arpita Dutt headshot

                      Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug

                      Key highlights include regulatory updates from Exelixis (EXEL) and Spark Therapeutics and pipeline updates from Regeneron and Ionis among others.

                        The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO

                        The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO

                          Arpita Dutt headshot

                          3 Biotech and Pharma Stocks with Key FDA Catalysts this October

                          Here is a look at three biotech and pharma stocks including Flexion (FLXN) that have an important regulatory event lined up this month.

                            Mallinckrodt (MNK) Closes InfaCare Pharmaceutical Buyout

                            Mallinckrodt (MNK) acquires privately-held InfaCare Pharmaceutical Corporation to diversify portfolio.

                              Intercept (ICPT) Provides Safety Guidelines For Ocaliva

                              Intercept Pharmaceuticals, Inc. (ICPT) provided a statement on the recent safety and dosing issues for lead drug Ocaliva and reinforced that the recommended dosing is safe.

                                Infinity/ Bristol-Myers Adds TNBC Patients to Clinical Deal

                                Infinity (INFI) expanded its existing clinical collaboration with Bristol-Myers Squibb for evaluating IPI-549 in combination with Opdivo to include patients with triple negative breast cancer.

                                  Abbvie/Bristol-Myers Inks Deal to Develop Therapeutic Cancer

                                  AbbVie (ABBV) and Bristol-Myers Squibb entered into a deal to evaluate the combination of ABBV-399 and Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer.

                                    The Medicines Co. Continues to Focus on Pipeline Development

                                    The Medicines Co.'s (MDCO) divestment of non-core assets should allow the company to focus on key assets and brings in a non-dilutive source of funds as well.

                                      Bayer (BAYRY) Focuses on Pipeline Development & Acquisitions

                                      Bayer (BAYRY) remains focused on developing its pipeline and acquisitions in order to boost its portfolio.

                                        Dr. Reddy's Laboratories (RDY) Surges: Stock Moves 5.7% Higher

                                        Dr. Reddy's Laboratories (RDY) was a big mover last session, as the company saw its shares rise nearly 6% on the day amid huge volumes.

                                          Werner Enterprises, Cott, Akari Therapeutics, and Alexion highlighted as Zacks Bull and Bear of the Day

                                          Werner Enterprises, Cott, Akari Therapeutics, and Alexion highlighted as Zacks Bull and Bear of the Day

                                            Madeleine Johnson headshot

                                            Akari Therapeutics (AKTX) Stock is Skyrocketing Over 60% Today: Here's Why

                                            On Thursday, shares of biopharmaceutical company Akari Therapeutics (AKTX) are skyrocketing, up over 60% in midday trading--the stock was up 90% in premarket trading--after it announced it would advance its lead drug candidate.

                                              Alnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up

                                              Alnylam (ALNY) and partner Sanofi RNAi therapeutic patisiran met its primary efficacy endpoint and all secondary endpoints in the phase III APOLLO study.

                                                Karyopharm's Liposarcoma Candidate Superior in Phase II Study

                                                Karyopharm's (KPTI) selinexor reduced the risk of progression or death in previously treated patients with advanced dedifferentiated liposarcoma.

                                                  Alnylam Pharmaceuticals (ALNY) Soars: Stock Adds 51.7% in Session

                                                  Alnylam Pharmaceuticals (ALNY) saw a big move last session, as its shares jumped nearly 52% on the day, amid huge volumes.